New York City, New York May 20, 2022 (Issuewire.com) - Creative Biolabs updated several new services today that eye on the construction of single-domain antibody libraries for SARS-CoV-2 variants neutralization after a study published in PNAS indicates the therapeutic potential of dromedary camel single-domain antibodies against COVID-19.
The prevalence of diseases such as COVID-19 and the growing need for immunotherapy are driving the development of technologies, including antibody libraries, which target disease-causing cells and organisms. Research published in PNAS found that dromedary camel single-domain antibodies (sdAbs) isolated from their dromedary camel VHH phage libraries can broadly neutralize SARS-CoV-2 variants with high affinity, which proves their therapeutic potential against COVID-19.
As a life science company dedicated to the development and application of single-domain antibodies, Creative Biolabs takes on the production of camelid antibodies and the construction of related immune antibody libraries for applications like diagnosis, bioimaging, antiviral drug screening, and targeting therapy against SARS-CoV-2 variants and future emerging viruses.
- Single Domain Antibody Production
Besides conventional antibodies, the Camelidae family, including llamas, camels, and alpacas, can produce another type of camelid antibody that is made up of only 2 heavy chains containing only the VHH region for antigen binding, which are later known as VHH antibodies, single-domain antibodies. Camelid antibody production with various modifications can be easily completed at Creative Biolabs leveraging different constructs, expression systems, fusion tags, labels, and cell lines, be it general production or large-scale manufacturing demands.
- Immune sdAb Library Construction
Antibody libraries allow researchers to search for the most effective antibody against a pathogen from a library of existing antibodies, which can significantly speed up the drug discovery process. Different from naïve libraries that use antibodies harvested from unimmunized subjects, Creative Biolabs prepares immune sdAb libraries using antibodies from immunized humans or animals without changing the immune specificity. Thus, generating sdAbs with unique specificity and high affinity can be guaranteed by Creative Biolabs' immune sdAb library construction service.
"Single domain antibodies present great potential in both therapeutic and diagnostic division. Our mission has always been to provide the very best outcome with our services," said the Head of the sdAb Research Department at Creative Biolabs. "We can build a custom immune sdAb library for every specific project, especially for the isolation of neutralizing sdAbs against SARS-CoV-2. And we will continue to engage in investigating and developing single domain antibodies for more applications and deliver our services to the research community."
About Creative Biolabs
Creative Biolabs contributes to advancing drug discovery and therapeutics development with products, services, and solutions that will enable researchers to succeed in their projects with lower overall costs. Being reputed as a perfect sdAb development program partner, Creative Biolabs has empowered numerous global research projects with its one-stop single domain antibody products and services.
For more information, please visit https://www.creative-biolabs.com/sdab/.
Media Contact
Creative Biolabs marketing@creative-biolabs.com https://www.creative-biolabs.com
